This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cote, P. Articles by David, P. Search for Related Content PubMed PubMed Citation Articles by Cote, P. Articles by David, P.

Circulation, Vol 59, 1165-1172, Copyright © 1979 by American Heart Association

ARTICLES

Effects of amiodarone on cardiac and coronary hemodynamics and on myocardial metabolism in patients with coronary artery disease

P Cote, MG Bourassa, J Delaye, A Janin, R Froment and P David

While the antiarrhythmic effects of amiodarone are well-documented, its hemodynamic effects are not. We injected 5 mg/kg amiodarone i.v. in 16 patients undergoing coronary arteriography. Heart rate did not change. Aortic (systolic, diastolic and mean) and left ventricular (systolic and end-diastolic) pressures decreased significantly (p less than 0.01) at 5 and 15 minutes; systemic vascular resistance also fell significantly (p less than 0.05), while cardiac index increased slightly but significantly (p less than 0.05). Coronary vascular resistance decreased significantly (p less than 0.01) and coronary sinus blood flow rose in most patients, from a mean of 138 ml/min to 153 ml/min at 5 minutes (p less than 0.02); it then returned toward the control value at 15 minutes (mean 145 ml/min). Myocardial metabolism of O2 was normal and unchanged. Metabolism of lactate improved in five patients, remained unchanged in seven and deteriorated transiently in four. No undesirable hemodynamic and clinical side effects occurred when the drug was administered slowly. We conclude that amiodarone is a powerful systemic and coronary vasodilator. In addition to its present indications in the treatment of angina pectoris and arrhythmias, the drug might be very useful as an afterload-reducing agent.

This article has been cited by other articles:

				S. C. Stamou, P. C. Hill, G. A. Sample, E. Snider, A. J. Pfister, R. C. Lowery, and P. J. Corso Prevention of Atrial Fibrillation After Cardiac Surgery : The Significance of Postoperative Oral Amiodarone Chest, December 1, 2001; 120(6): 1936 - 1941. [Abstract] [Full Text] [PDF]

				K. Katariya, E. DeMarchena, and H. Bolooki Oral amiodarone reduces incidence of postoperative atrial fibrillation Ann. Thorac. Surg., November 1, 1999; 68(5): 1599 - 1603. [Abstract] [Full Text] [PDF]

				G. Solares, F. Ramos, R. Martin-Duran, and M. Ares Is Amiodarone an Alternative to Beta-Blockers to Treat Supraventricular Tachycardias in Pheochromocytoma? Arch Intern Med, October 1, 1986; 146(10): 2085 - 2085. [Abstract] [PDF]

				A. J. Flach, B. J. Dolan, B. Sudduth, and J. Weddell Amiodarone-Induced Lens Opacities Arch Ophthalmol, October 1, 1983; 101(10): 1554 - 1556. [Abstract] [PDF]

				L. J. Kaplan and W. E. Cappaert Amiodarone Keratopathy: Correlation to Dosage and Duration Arch Ophthalmol, April 1, 1982; 100(4): 601 - 602. [Abstract] [PDF]